ID   IGR-CaP1-R-caba
AC   CVCL_WM75
DR   cancercelllines; CVCL_WM75
DR   Wikidata; Q94314872
RX   PubMed=27198502;
CC   Selected for resistance to: ChEBI; CHEBI:63584; Cabazitaxel.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Prostate; UBERON=UBERON_0002367.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A018 ! IGR-CaP1
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 05-10-23; Version: 7
//
RX   PubMed=27198502; DOI=10.15252/emmm.201506059;
RA   Al Nakouzi N., Wang C.K.-D., Beraldi E., Jager W., Ettinger S.,
RA   Fazli L., Nappi L., Bishop J., Zhang F., Chauchereau A., Loriot Y.,
RA   Gleave M.E.;
RT   "Clusterin knockdown sensitizes prostate cancer cells to taxane by
RT   modulating mitosis.";
RL   EMBO Mol. Med. 8:761-778(2016).
//